<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HCA2BC6178B994630A054D1AA69FF65B9" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 2821 IH: FDA Modernization Act 3.0</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-04-10</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 2821</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250410">April 10, 2025</action-date><action-desc><sponsor name-id="C001103">Mr. Carter of Georgia</sponsor> (for himself, <cosponsor name-id="B001300">Ms. Barrag&#225;n</cosponsor>, <cosponsor name-id="B001260">Mr. Buchanan</cosponsor>, <cosponsor name-id="D000216">Ms. DeLauro</cosponsor>, <cosponsor name-id="H001086">Mrs. Harshbarger</cosponsor>, and <cosponsor name-id="C001125">Mr. Carter of Louisiana</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods.</official-title></form><legis-body id="HB3E3065747F0460C8B65C301F9903B4C" style="OLC"> 
<section id="H4FEB365A4D414A16A161549540D278E0" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>FDA Modernization Act 3.0</short-title></quote>.</text></section> <section id="HAE075D9E988D48B7A0F081335B4ED3D6"><enum>2.</enum><header>Regulations on nonclinical testing methods</header> <subsection id="H8B171CE158794233B17E110AFF2BF767"><enum>(a)</enum><header>Interim final rule</header> <paragraph commented="no" display-inline="no-display-inline" id="HD8D82A1573A246DCB65F09FF73945B1D"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">In order to ensure implementation of the amendments to section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>) made by section 3209(a) of the Consolidated Appropriations Act, 2023 (<external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>; 136 Stat. 5821), not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall publish an interim final rule—</text> 
<subparagraph commented="no" display-inline="no-display-inline" id="H21D7D79D0F5145AAAA6A4851EAF41DC8"><enum>(A)</enum><text display-inline="yes-display-inline">to amend the sections of title 21, Code of Federal Regulations, described in paragraph (2) to replace any references to <quote>animal</quote> tests, data, studies, models, and research with a reference to nonclinical tests, data, studies, models, and research; and</text></subparagraph> <subparagraph commented="no" display-inline="no-display-inline" id="HF872BD371F2B474ABEAAEA1FA5F4AE42"><enum>(B)</enum><text>to add the definition of <term>nonclinical test</term> in section 505(z) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(z)</external-xref>) to sections 312.3, 314.3, 315.2, and 601.31 of title 21, Code of Federal Regulations. </text></subparagraph></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H1F0F2B9BBC7B4CF2A8EF30F2089C1C28"><enum>(2)</enum><header>CFR sections described</header><text>The sections of title 21, Code of Federal Regulations, described in this paragraph are the following:</text> <subparagraph id="HF757766C020D4C8EA864121E5D8C9161"><enum>(A)</enum><text>Section 312.22(c).</text></subparagraph> 
<subparagraph id="H6CF60F0FF29F4C3298B836C863A2C9BB"><enum>(B)</enum><text>Section 312.23(a)(3)(iv).</text></subparagraph> <subparagraph id="HA350B478457648CB9B8E94E5E34E809F"><enum>(C)</enum><text>Section 312.23(a)(5)(ii).</text></subparagraph> 
<subparagraph id="HCD25F53014F64D93B5C9CEF3B5A24EA6"><enum>(D)</enum><text>Section 312.23(a)(5)(iii).</text></subparagraph> <subparagraph id="H26F0A602E6A04A8A955C635D324EAA6F"><enum>(E)</enum><text>Section 312.23(a)(8).</text></subparagraph> 
<subparagraph id="H884BECE813584CA09418B90B53BB00A4"><enum>(F)</enum><text>Section 312.23(a)(8)(i).</text></subparagraph> <subparagraph id="H56A61335DC634DD5B7DDB457351D363A"><enum>(G)</enum><text>Section 312.23(a)(8)(ii).</text></subparagraph> 
<subparagraph id="HC5FB4537537B4AC3832FE58AB12B4A67"><enum>(H)</enum><text>Section 312.23(a)(10)(i).</text></subparagraph> <subparagraph id="H75EFD1A566A34AAD92E65328A818CA8C"><enum>(I)</enum><text>Section 312.23(a)(10)(ii).</text></subparagraph> 
<subparagraph id="H6042668C73A84993B5DF238F88B848B7"><enum>(J)</enum><text>Section 312.33(b)(6).</text></subparagraph> <subparagraph id="H3D8CAAB98DF5420D9CC5D714FDAE69D7"><enum>(K)</enum><text>Section 312.82(a).</text></subparagraph> 
<subparagraph id="HC2513F60BAB044A6B042BF860AB7F9AF"><enum>(L)</enum><text>Section 312.88.</text></subparagraph> <subparagraph id="H27A9BC54AE0C4D248A0EF2AA4FE47E53"><enum>(M)</enum><text>Section 314.50(d)(2).</text></subparagraph> 
<subparagraph id="H5EBAC274B53E401CB34A4FB5417C94B7"><enum>(N)</enum><text>Section 314.50(d)(2)(iv).</text></subparagraph> <subparagraph id="HD85581E20DFD4A9EB939BEB4E4D49C50"><enum>(O)</enum><text>Section 314.50(d)(5)(i).</text></subparagraph> 
<subparagraph id="H8A47A03BF1AA45568738F40A1690FD28"><enum>(P)</enum><text>Section 314.50(d)(5)(vi)(a).</text></subparagraph> <subparagraph id="H21D2CC28AE3B4D2AB66A8FA7D28DEE4F"><enum>(Q)</enum><text>Section 314.50(d)(5)(vi)(b).</text></subparagraph> 
<subparagraph id="H87F6F1D9E09E45E9B003C07C8C21523A"><enum>(R)</enum><text>Section 314.93(e)(2).</text></subparagraph> <subparagraph id="H0C09950B80DC4D78AFDB612BB3E893FE"><enum>(S)</enum><text>Section 315.6(d).</text></subparagraph> 
<subparagraph id="HE28C0BDA64BE42BA9CB035415EE33D69"><enum>(T)</enum><text>Section 330.10(a)(2).</text></subparagraph> <subparagraph id="H28FE6016A3F64AC797A198B949F2544B"><enum>(U)</enum><text>Section 601.35(d).</text></subparagraph> 
<subparagraph id="HBBBEB40276B0411AA303AE7848B0B73C"><enum>(V)</enum><text>Any other section necessary to ensure regulatory consistency with the amendments to section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>) made by section 3209(a) of the Consolidated Appropriations Act, 2023 (<external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>; 136 Stat. 5821). </text></subparagraph></paragraph> <paragraph id="H18DA6385C36D4267855E453F8658B674"><enum>(3)</enum><header>Effectiveness of interim final rule</header><text>Notwithstanding subparagraph (B) of section 553(b) of title 5, United States Code, the interim final rule issued by the Secretary of Health and Human Services under paragraph (1) shall become immediately effective as an interim final rule without requiring the Secretary of Health and Human Services to demonstrate good cause therefor. </text></paragraph></subsection> 
<subsection id="H11F0F13383AA475588365EF05D413717" commented="no" display-inline="no-display-inline"><enum>(b)</enum><header>Technical amendment</header><text>Section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) is amended by designating the second subsection (z) (relating to clinical trial diversity action plans), as added by section 3601(a) of the Health Extenders, Improving Access to Medicare, Medicaid, and CHIP, and Strengthening Public Health Act of 2022 (division FF of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>), as subsection (aa). </text></subsection></section> </legis-body></bill>

